

NEW ZEALAND DATA SHEET

NORSPAN® TRANSDERMAL PATCH

Buprenorphine

1 PRODUCT NAME

NORSPAN® 5mg Patch

NORSPAN® 10mg Patch

NORSPAN® 20mg Patch

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

NORSPAN® patch 5

Each square patch releases buprenorphine 5 micrograms per hour over 7 days

The area containing the active substance: 6.25 cm²

Total buprenorphine content: 5mg

NORSPAN® patch 10

Each rectangular patch releases buprenorphine 10 micrograms per hour over 7 days

The area containing the active substance: 12.5 cm²

Total buprenorphine content: 10mg

NORSPAN® patch 20

Each square patch releases buprenorphine 20 micrograms per hour over 7 days

The area containing the active substance: 25 cm²

Total buprenorphine content: 20mg

For full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

NORSPAN® patch is either rectangular (10 micrograms/hr) or square (5 and 20 micrograms/hr) beige coloured matrix patch with rounded corners, marked with the trade name and consisting of a protective liner and functional layers. Proceeding from the outer surface towards the surface adhering to the skin, the layers are (1) a beige-coloured web backing layer of polyester material; (2) an adhesive matrix rim without buprenorphine; (3) a separating layer (“foil”) consisting of polyethylene terephthalate over the adhesive matrix; (4) the buprenorphine-containing adhesive matrix; and (5) a release liner. Before use the release liner covering the adhesive layer is removed and discarded.




Figure 1: Cross section drawing of NORSPAN® patch

NEW ZEALAND DATA SHEET

NORSPAN® patch is available in three different strengths: 5 micrograms per hour, 10 micrograms per hour and 20 micrograms per hour. The composition of all three strengths is identical except for patch size. The proportion of buprenorphine in the adhesive matrix is the same in each strength (10% by weight). The amount of buprenorphine released from each system per hour is proportional to the surface area of the patch. The skin is the limiting barrier to diffusion from the system into the bloodstream.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Management of moderate to severe pain.

4.2 Dose and method of administration

For application to the skin only (transdermal use) over 7 days.

Adults

The lowest dose, NORSPAN® patch 5 micrograms per hour should be used as the initial dose. Consideration should be given to the previous opioid history of the patient, including opioid tolerance, if any, as well as current general condition and medical status of the patient. No dosage adjustment is necessary in the elderly.

Titration

Discontinue all other around-the-clock opioid drugs when NORSPAN® patch is initiated.

During initiation and titration with NORSPAN® patch, patients should take the usual recommended doses of short-acting supplemental analgesics as needed until analgesic efficacy with NORSPAN® patch is attained.

During the titration process, the dose may be adjusted every 3-days (72 hours). Thereafter, the 7-day dosing interval should be maintained. Changes in NORSPAN® patch dosage may be individually titrated based on the need for supplemental when necessary (PRN) analgesia and the patient's response to NORSPAN® patch.

To increase the dose, the patch that is currently being worn should be removed and a higher strength of NORSPAN® patch or a combination of patches should be applied at a different skin site to achieve the required dose. A new patch should not be applied to the same skin site for three. It is recommended that no more than two patches be applied at the same time, up to a maximum total dose of 40 micrograms/hr.

Patients should be carefully and regularly monitored to assess the optimum dose and duration of treatment. Titration should continue every three to seven days until adequate analgesia and improvement in function is achieved. If adequate pain relief cannot be achieved with maximal doses of NORSPAN® patch, the patient should be converted to an around-the-clock strong opioid.

Opioid Naïve Patients

In situations when it is clinically indicated to initiate opioid therapy with a maintenance (around-the-clock) opioid in an opioid naïve patient, clinical trials have shown that NORSPAN® patch is an appropriate opioid product. The lowest dose available (NORSPAN® patch 5 micrograms per hour) should be used as the initial dose. If the patient is taking supplemental analgesics, these may be continued on a PRN basis as the dose of NORSPAN® patch is adjusted.

NEW ZEALAND DATA SHEET

Conversion from Opioid or Fixed Ratio Opioid/Non-Opioid Combination Medicines

NORSPAN® patch has been used as a treatment alternative in patients taking lower doses of opioids (up to 90mg of oral morphine-equivalents a day) and combination analgesics. Patients who have had previous exposure to oral opioids should be started on a low dose of Norspan®. Titration of Norspan® to the optimal dose should be supported by the use of rescue analgesics.

Children

Use in children is not recommended due to lack of clinical safety and efficacy data in patients under 18 years of age.

Renal and Hepatic Impairment

No dosage adjustment is required in patients with renal impairment or mild to moderate hepatic impairment. Patients with severe hepatic impairment may accumulate buprenorphine and NORSPAN® patch should be used with caution, if at all, in such patients.

Discontinuation

During chronic therapy, periodically reassess the continued need for opioid analgesics. After the removal of a NORSPAN® patch buprenorphine serum concentrations decrease gradually, and the analgesic effect is maintained for a certain amount of time. This needs to be considered when use of NORSPAN® patch is to be followed by other opioids. As a general rule, a subsequent opioid should not be administered within 24 hours of removal of a NORSPAN® patch.

When the patient no longer requires therapy with NORSPAN® patch, use a gradual downward titration of the dose every 7 days to prevent signs and symptoms of withdrawal in the physically dependent patient; consider introduction of an appropriate immediate-release opioid medication.

Do not abruptly discontinue NORSPAN® patch.

Method of Application

In order to ensure effective analgesia of buprenorphine and to minimise the potential of skin reactions (see section 4.4), the following directions of use should be followed:

NORSPAN® patch should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest, but not to any parts of the skin with large scars. Application sites should be rotated whenever a system is replaced or added. A new patch should not be applied to the same application site for 3-4 weeks. NORSPAN® patch should be applied to a relatively hairless or nearly hairless skin site. If none are available, the hair at the site should be cut with scissors, not shaven.

If the application site must be cleaned, it should be done with clean water only. Soaps, alcohol, oils, lotions or abrasive devices should not be used. The skin should be dry before the patch is applied. NORSPAN® patch should be applied immediately after removal from the sealed pouch packaging. Following removal of the release liner, the patch should be pressed firmly in place with the palm of the hand for approximately 30 seconds, making sure the contact is complete, especially around the edges. If the edges of the patch begin to peel off, they may be taped down with suitable skin tape. The patch should be worn continuously for 7 days.

Bathing, showering, or swimming should not affect the patch. If a patch falls off, a new one should be applied.

While wearing the NORSPAN® patch patients should be advised to avoid exposing the application site to direct external heat sources, such as heating pads, electric blankets, hot water bottles, heat lamps, etc; as an increase in the absorption of buprenorphine may occur. The effects of use in hot tubs and sauna has not been studied.

NEW ZEALAND DATA SHEET

When changing a patch, patients should be instructed to remove the used NORSPAN® patch, fold it over on itself (bringing the adhesive sides together) and dispose of safely, out of reach of children.

4.3 Contraindications

NORSPAN® patch is contraindicated in patients with known hypersensitivity to buprenorphine or any components of the patch (see Section 6.1), including previous history of application site reactions suggestive of allergic contact dermatitis with buprenorphine transdermal patches, myasthenia gravis, delirium tremens and pregnancy.

NORSPAN® patch is contraindicated in patients with severely impaired respiratory function and in patients concurrently receiving non-selective monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping treatment with non-selective MAOIs.

NORSPAN® patch must not be used for the treatment of opioid dependence and opioid withdrawal.

4.4 Special warnings and precautions for use

NORSPAN® should be used with caution in patients with:

- Severely impaired respiratory function
- Sleep apnoea
- CNS depressants co-administration (see below and section 4.5)
- Serotonergic agents (see below and section 4.5)
- Tolerance, physical dependence and withdrawal (see below)
- Psychological dependence (addiction), abuse profile and history of substance and/or
- Alcohol abuse (see below)
- Head injury, intracranial lesions or increased intracranial pressure, shock, a reduced level of consciousness of uncertain origin
- Severely impaired hepatic function (see section 4.2)
- Constipation

Use with caution in patients with hypotension, hypovolaemia, biliary tract disease, pancreatitis, inflammatory bowel disorders, prostatic hypertrophy, adrenocortical insufficiency, chronic renal and hepatic disease and debilitated patients. As with all opioids, a reduction in dose may be advisable in hypothyroidism.

Hazardous and harmful use

NORSPAN® contains the opioid buprenorphine and is a potential drug of abuse, misuse and addiction.

Addiction can occur in patients appropriately prescribed NORSPAN® at recommended doses.

The risk of addiction is increased in patients with a personal or family history of substance abuse (including alcohol and prescription and illicit drugs) or mental illness. The risk also increases the longer the drug is used and with higher doses. Patients should be assessed for their risks for opioid abuse or addiction prior to being prescribed NORSPAN®.

All patients receiving opioids should be routinely monitored for signs of misuse and abuse. Opioids are sought by people with addiction and may be subject to diversion. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on the safe storage and proper disposal of any unused drug (see *section 6.4 and section 6.6*). Caution patients that abuse of oral or transdermal forms of opioids by parenteral administration can result in serious adverse events, which may be fatal.

Patients should be advised not to share NORSPAN® with anyone else.

Significant respiratory depression has been associated with buprenorphine, particularly by the intravenous route. A number of deaths have occurred when addicts have intravenously abused buprenorphine, usually with benzodiazepines concomitantly. Additional overdose deaths due to ethanol

NEW ZEALAND DATA SHEET

and benzodiazepines in combination with buprenorphine have been reported. Caution should be exercised when prescribing NORSPAN® to patients known to have, or suspected of having, problems with drug or alcohol abuse or serious mental illness.

Although the risk of addiction in any individual is unknown, it may occur in patients appropriately prescribed NORSPAN® patch and in those who obtain the drug illicitly. Psychological and/or physical dependence may occur at recommended doses and if the drug is misused or abused.

Assess each patient's risk for addiction to opioids, abuse, or misuse prior to prescribing NORSPAN® patch and monitor all patients receiving NORSPAN® patch for the development of these behaviours or conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression).

The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids, but use in such patients necessitates comprehensive counselling about the risks and proper use of opioids, along with close monitoring for signs of addiction, abuse, or misuse.

NORSPAN® patch, like other opioids, can be diverted for non-medical use into illicit channels of distribution. NORSPAN® patch should therefore be prescribed and handled with a high degree of caution appropriate to the use of a drug with strong abuse potential.

NORSPAN® patch is intended for transdermal use only. Abuse of opioids poses a risk of overdose and death. This risk is increased with concurrent abuse of opioids with alcohol and other substances including other opioids and benzodiazepines. Abuse or misuse in ways other than indicated or intentional compromise of transdermal delivery systems containing opioids will result in the uncontrolled delivery of the opioid and pose a significant risk to the abuser that could result in overdose and death (see Section 4.9 OVERDOSAGE).

Respiratory depression

Serious, life-threatening or fatal respiratory depression can occur with the use of opioids even when used as recommended. It can occur at any time during the use of [Product] but the risk is greatest during initiation of therapy or following an increase in dose. Patients should be monitored closely for respiratory depression at these times.

The risk of life-threatening respiratory depression is also higher in elderly, frail, or debilitated patients and in patients with existing impairment of respiratory function (e.g. chronic obstructive pulmonary disease; asthma). Opioids should be used with caution and with close monitoring in these patients (see *section 4.2*). The use of opioids is contraindicated in patients with severe respiratory disease, acute respiratory disease and respiratory depression (see *section 4.3*).

The risk of respiratory depression is greater with the use of high doses of opioids, especially high potency and modified release formulations, and in opioid naïve patients. Initiation of opioid treatment should be at the lower end of the dosage recommendations with careful titration of doses to achieve effective pain relief. Careful calculation of equianalgesic doses is required when changing opioids or switching from immediate release to modified release formulations, (see *section 4.2*).

Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. Opioids may also cause worsening of pre-existing sleep apnoea (see *section 4.8*). In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper.

NEW ZEALAND DATA SHEET

Risks from concomitant use of benzodiazepines or other CNS depressants, including alcohol

Concomitant use of opioids and benzodiazepines or other CNS depressants, including alcohol, may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing of NORSPAN® with CNS depressant medicines, such as other opioid analgesics, benzodiazepines, gabapentinoids, cannabis, sedatives, hypnotics, tricyclic antidepressants, antipsychotics, antihistamines, centrally-active anti-emetics and other CNS depressants, should be reserved for patients for whom other treatment options are not possible. If a decision is made to prescribe NORSPAN® concomitantly with any of the medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible. Patients should be followed closely for signs and symptoms of respiratory depression and sedation. Patients and their caregivers should be made aware of these symptoms. Patients and their caregivers should also be informed of the potential harms of consuming alcohol while taking NORSPAN®.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of medicine-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics (see Section 4.5 Interactions with other medicines and other forms of interaction).

Advise both patients and caregivers about the risks of respiratory depression and sedation when NORSPAN® patch is used with benzodiazepines or other CNS depressants (including alcohol and illicit drugs). Advise patients not to drive or operate heavy machinery until the effects of concomitant use of the benzodiazepine or other CNS depressant have been determined. Screen patients for risk of substance use disorders, including opioid abuse and misuse, and warn them of the risk for overdose and death associated with the use of additional CNS depressants including alcohol and illicit drugs (see Section 4.5 Interactions with other medicines and other forms of interaction).

Use of opioids in chronic (long-term) non-cancer pain (CNCP)

Opioid analgesics have an established role in the treatment of acute pain, cancer pain and palliative and end-of-life care. Current evidence does not generally support opioid analgesics in improving pain and function for most patients with chronic non-cancer pain. The development of tolerance and physical dependence and risks of adverse effects, including hazardous and harmful use, increase with the length of time a patient takes an opioid. The use of opioids for long-term treatment of CNCP is not recommended.

The use of an opioid to treat CNCP should only be considered after maximised non-pharmacological and non-opioid treatments have been tried and found ineffective, not tolerated or otherwise inadequate to provide sufficient management of pain. Opioids should only be prescribed as a component of comprehensive multidisciplinary and multimodal pain management.

Opioid therapy for CNCP should be initiated as a trial in accordance with clinical guidelines and after a comprehensive biopsychosocial assessment has established a cause for the pain and the appropriateness of opioid therapy for the patient (see *Hazardous and harmful use, above*). The expected outcome of therapy (pain reduction rather than complete abolition of pain, improved function and quality of life) should be discussed with the patient before commencing opioid treatment, with agreement to discontinue treatment if these objectives are not met.

Owing to the varied response to opioids between individuals, it is recommended that all patients be started at the lowest appropriate dose and titrated to achieve an adequate level of analgesia and functional improvement with minimum adverse reactions. Immediate-release products should not be used to treat chronic pain, but may be used for a short period in opioid-naïve patients to develop a level of tolerance before switching to a modified-release formulation. Careful and regular assessment and monitoring is required to establish the clinical need for ongoing treatment. Discontinue opioid therapy if there is no improvement of pain and/or function during the trial period or if there is any evidence of misuse or abuse. Treatment should only continue if the trial has demonstrated that the pain is opioid

NEW ZEALAND DATA SHEET

responsive and there has been functional improvement. The patient's condition should be reviewed regularly and the dose tapered off slowly if opioid treatment is no longer appropriate (see *Ceasing Opioids*).

Tolerance, physical dependence and withdrawal

Buprenorphine is a μ -opioid agonist.

Neuroadaptation of the opioid receptors to repeated administration of opioids can produce tolerance and physical dependence. Tolerance is the need for increasing doses to maintain analgesia. Tolerance may occur to both the desired and undesired effects of the opioid.

Physical dependence, which can occur after several days to weeks of continued opioid usage, results in withdrawal symptoms if the opioid is ceased abruptly or the dose is significantly reduced.

Withdrawal symptoms can also occur following the administration of an opioid antagonist (e.g. naloxone) or partial agonist (e.g. buprenorphine). Withdrawal can result in some or all of the following symptoms: dysphoria, restlessness/agitation, lacrimation, rhinorrhoea, yawning, sweating, chills, myalgia, mydriasis, irritability, anxiety, increasing pain, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhoea, increased blood pressure, increased respiratory rate and increased heart rate.

When discontinuing NORSPAN® in a person who may be physically-dependent, the drug should not be ceased abruptly but withdrawn by tapering the dose gradually (see *section 4.2*).

If NORSPAN® patch is abruptly discontinued in a physically-dependent patient, an abstinence syndrome may occur. Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. Withdrawal may also be precipitated through the administration of drugs with opioid antagonist activity, e.g., naloxone, or mixed agonist/antagonist analgesics (pentazocine).

Administration of buprenorphine to persons who are physically dependent on full μ -opioid agonists may precipitate an abstinence syndrome depending on the level of physical dependence, and the timing and dose of buprenorphine.

Accidental exposure

Accidental exposure of NORSPAN®, especially by children, can result in a fatal overdose of NORSPAN®. Patients and their caregivers should be given information on safe storage and disposal of unused NORSPAN® (see *section 6.4 and section 6.6*).

Hyperalgesia

Hyperalgesia may occur with the use of opioids, particularly at high doses. Hyperalgesia may manifest as an unexplained increase in pain, increased levels of pain with increasing opioid dosages or diffuse sensitivity not associated with the original pain. Hyperalgesia should not be confused with tolerance (see *Tolerance, dependence and withdrawal*). If opioid induced hyperalgesia is suspected, the dose should be reduced and tapered off if possible. A change to a different opioid may be required.

Ceasing opioids

Abrupt discontinuation or rapid decreasing of the dose in a person physically dependent on an opioid may result in serious withdrawal symptoms and uncontrolled pain (see *Tolerance, dependence and withdrawal*). Such symptoms may lead the patient to seek other sources of licit or illicit opioids. Opioids should not be ceased abruptly in a patient who is physically dependent but withdrawn by tapering the dose slowly. Factors to take into account when deciding how to discontinue or decrease therapy include

NEW ZEALAND DATA SHEET

the dose and duration of the opioid the patient has been taking, the type of pain being treated and the physical and psychological attributes of the patient. A multimodal approach to pain management should be in place before initiating an opioid analgesic taper. During tapering, patients require regular review and support to manage any increase in pain, psychological distress and withdrawal symptoms.

There are no standard tapering schedules suitable for all patients and an individualised plan is necessary. In general, tapering should involve a dose reduction of no more than 10 percent to 25 percent every 2 to 4 weeks (see *section 4.2*). If the patient is experiencing increased pain or serious withdrawal symptoms, it may be necessary to go back to the previous dose until stable before proceeding with a more gradual taper.

When ceasing opioids in a patient who has a suspected opioid use disorder, the need for medication assisted treatment and/or referral to a specialist should be considered.

General

In chronic non-malignant pain, medication modifies the pain only to some extent. A comprehensive assessment is essential, and non-pharmacological options should be explored before starting pharmacological therapy. Patients should be advised about the expected outcome of therapy (i.e. pain reduction rather than complete abolition of pain, reduced suffering, improved function and quality of life). Opioid therapy should be initiated as a trial. Careful and regular assessment and monitoring is required to establish the clinical need for ongoing treatment with an opioid analgesic. Reassess or discontinue opioid therapy if there is no improvement of pain and/or function. NORSPAN® patch should be ceased if there is any evidence of misuse or abuse, or if NORSPAN® patch is having a detrimental effect.

Use in surgery

NORSPAN® is not recommended for analgesia in the immediate post-operative period or in other situations characterized by rapidly varying analgesic requirement. As with all opioid preparations patients who are to undergo cordotomy or other pain-relieving surgical procedures should not use NORSPAN® patch for at least 24 hours prior to surgery. NORSPAN® patch should be used with caution following abdominal surgery, as opioids are known to impair intestinal motility.

Febrile illness

A kinetic study indicated no alteration of buprenorphine plasma concentrations in subjects with mild fever induced by endotoxin administration. However, because increased blood flow to the skin may enhance absorption, severe febrile illness may increase the rate of buprenorphine absorption from the patch and thus, patients with severe febrile illness should be monitored for side effects and may require dose adjustment.

Use in patients with seizures

Buprenorphine may lower the seizure threshold in patients with a history of seizure disorder.

Opioid-Naïve Patients

The lowest dose available, NORSPAN® patch 5 micrograms, should be used as the starting dose in opioid-naïve patients.

Renal Impairment

No dose adjustment is necessary in patients with renal impairment.

Hepatic Impairment

Buprenorphine is metabolised in the liver. No dose adjustment is necessary in patients with mild to moderate hepatic impairment, however, the intensity and duration of its action may be affected in patients with impaired liver function.

Patients with severe hepatic impairment may accumulate buprenorphine during NORSPAN® patch treatment. Consideration should be given to alternative therapy and NORSPAN® patch should be used

NEW ZEALAND DATA SHEET

with caution, if at all, in such patients.

Effect on laboratory tests

Increased alanine aminotransferase levels.

Application of External Heat

Advise patients and their caregivers to avoid exposing the application site and surrounding area to direct external heat sources, such as heating pads or electric blankets, heat or tanning lamps, saunas, hot tubs, hot water bottles and heated water beds while wearing the patch because an increase in absorption of buprenorphine may occur. There is a potential for temperature-dependent increases in buprenorphine released from the patch, thereby increasing the risk of opioid reactions.

Skin reactions at application site

To minimise the risk of occurrence of application site skin reactions, it is important to follow the posology instructions (see section 4.2).

Application site reactions with NORSPAN® are usually presented by a mild or moderate skin inflammation (contact dermatitis), and their typical appearance may include erythema, oedema, pruritus, rash, small blisters (vesicles), and painful/burning sensation at the application site. Most commonly the cause is skin irritation (irritant contact dermatitis), and these reactions resolve spontaneously after NORSPAN® removal.

NORSPAN® may also cause skin sensitisation and subsequent allergic contact dermatitis (immune-mediated, type IV hypersensitivity reaction). Allergic contact dermatitis may develop with a significant delay (it may take months after NORSPAN® treatment initiation), and may manifest with symptoms similar to irritant contact dermatitis, or with more intense symptoms, such as “burn”-like lesions with bullae and discharge, which may spread outside the application site and which may not resolve rapidly after NORSPAN® removal. Patients and caregivers should be instructed accordingly to monitor the application sites for such reactions. If allergic contact dermatitis is suspected, relevant diagnostic procedures should be performed to determine if sensitisation has occurred and its actual cause (buprenorphine and/or other ingredients of the patch). If allergic contact dermatitis has been confirmed, treatment should be discontinued (see section 4.3). Continued NORSPAN® treatment in individuals experiencing allergic contact dermatitis may lead to complications, including blistering of the skin, open wound, bleeding, ulceration, and subsequent infections. Mechanical injuries during patch removal (e.g. laceration) are also possible in patients with fragile skin. Chronic inflammation may lead to long-lasting sequelae, such as post-inflammatory hyper- and hypopigmentation, as well as dry and thick scaly skin lesions, which may closely resemble scars.

Use in Children

The safety and efficacy of NORSPAN® patch in patients under 18 years of age has not been established.

4.5 Interaction with other medicines and other forms of interaction

Anti-ulcer medication

In clinical trial patients there were no apparent effects on NORSPAN® patch exposure when used concomitantly with various H2-antagonists or proton pump inhibitors.

Benzodiazepines and other Central Nervous System (CNS) depressants

The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).

Such agents include sedatives or hypnotics, general anaesthetics, other opioid analgesics, phenothiazines, centrally acting anti-emetics, benzodiazepines and alcohol

NEW ZEALAND DATA SHEET

CYP inhibitors and inducers

Buprenorphine is both a substrate for, and an inhibitor of, CYP3A4. Specific inhibitors of CYP3A4 (ketoconazole, ritonavir, indinavir) have been shown to inhibit formation of the buprenorphine metabolite, norbuprenorphine, in human liver microsomes. Antifungal drugs with similar CYP3A4 inhibiting properties to ketoconazole include fluconazole and itraconazole).

Buprenorphine is primarily metabolised by glucuronidation and to a lesser extent (about 30%) by CYP3A4. Concomitant treatment with CYP3A4 inhibitors may lead to elevated plasma concentrations with intensified efficacy of buprenorphine. A drug interaction study with the CYP3A4 inhibitor ketoconazole did not produce clinically relevant increases in mean maximum (C_{max}) or total (AUC) buprenorphine exposure following NORSPAN[®] with ketoconazole as compared to NORSPAN[®] alone.

The interaction between buprenorphine and CYP3A4 enzyme inducers has not been studied; however, co-administration of NORSPAN[®] patch and enzyme inducers (e.g. phenobarbitone, carbamazepine, phenytoin, rifampicin) could lead to increased clearance which might result in reduced efficacy. Buprenorphine has also been shown to be a CYP2D6 inhibitor in vitro. Patients receiving NORSPAN[®] with CYP3A4 inhibitors should be closely monitored.

General anaesthetics

Reductions in hepatic blood flow induced by some general anaesthetics (e.g. halothane) and other drugs may result in a decreased rate of hepatic elimination of buprenorphine.

Serotonergic agents

It is unknown whether there is an interaction between selective MAOIs (e.g. selegiline) and buprenorphine, hence, caution is advised with this drug combination.

Warfarin

The potential exists for international normalized ratio (INR) elevation in patients who are concomitantly taking warfarin. A retrospective safety analysis and benefit-risk assessment was performed evaluating the interaction between buprenorphine and warfarin. The analysis revealed very limited data was available and that there was a more likely interaction between buprenorphine and phenprocoumon than warfarin. However, there is not sufficient information for inclusion of the medicine interaction between buprenorphine and phenprocoumon.

Anticholinergics

Anticholinergics or other drugs with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor patients for signs of urinary retention or reduced gastric motility when NORSPAN[®] patch is used concurrently with anticholinergic drugs.

4.6 Fertility, pregnancy and lactation

Pregnancy

Buprenorphine has been shown to cross the placenta in humans and has been detected in newborn blood, urine and meconium. Opioid analgesics, including buprenorphine, may cause respiratory depression in the newborn infant. Withdrawal symptoms in newborn infants have been reported with prolonged use of this class of medicines. Neonatal withdrawal symptoms may include poor feeding, diarrhoea, irritability, tremor, rigidity, and seizures. Infants born to mothers physically dependent on opioids may also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms. There are no adequate and well-controlled studies of buprenorphine or NORSPAN[®] patch in pregnant women.

In pregnant rabbits, buprenorphine produced statistically significant pre-implantation losses at PO doses

NEW ZEALAND DATA SHEET

≥ 1mg/kg/day and post-implantation losses at intravenous (IV) doses ≥ 0.2mg/kg/day (medicine exposure in animals about 6 times the expected daily systemic dose of buprenorphine in humans during treatment with NORSPAN® patch 20mg, on a surface area basis). Dystocia was noted in pregnant rats treated intramuscular (IM) with buprenorphine doses > 1mg/kg/day (approximately 17 times the expected human daily dose during treatment with NORSPAN® patch 20mg). Fertility and peri- and post-natal development studies with buprenorphine in rats showed increases in neonatal mortality after doses of 0.8mg/kg/day PO, 0.5mg/kg/day IM or 0.1mg/kg/day SC (approximately 14, 9 and 1.7 times, respectively, the human daily dose during treatment with NORSPAN® patch 20mg on a mg/m² basis). No-effect doses for neonatal mortality were not established. Delays in the occurrence of righting reflex and startle response were noted in rat pups at a buprenorphine dose > 8mg/kg/day PO (> 100 times the expected human daily dose during treatment with NORSPAN® patch 20mg on a mg/m² basis). No evidence for teratogenic activity was observed in animal studies at buprenorphine doses ranging from 14 to > 100 times the expected human daily dose during treatment with NORSPAN® patch 20mg, on a surface area basis.

No effects on embryofetal development were noted in studies with topically applied NORSPAN® patch in rats and rabbits (systemic exposure to buprenorphine up to about 30 and 6 times, respectively, the expected human daily dose during treatment with NORSPAN® patch 20mg, on a surface area basis). However, systemic absorption was demonstrated only during late gestation in rabbits.

In a pre/postnatal study in pregnant and lactating rats, administration of ≥0.5 mg/kg/day SC buprenorphine caused an increase in the number of stillbirths and reduced pup survival. Exposures (AUC) at the no effect level (0.05 mg/kg/day SC) were subclinical.

Breastfeeding

Animal studies indicate buprenorphine has the potential to inhibit lactation or milk production. Decreases in post-natal survival, growth and development were also observed in animals treated with buprenorphine during lactation. Buprenorphine passes into mother's milk at low concentrations and therefore, NORSPAN® patch should not be used by breastfeeding women.

Fertility

No human data on the effect of buprenorphine on fertility are available. In animal studies, no effect on fertility has been observed with buprenorphine (see section 5.3)

4.7 Effects on ability to drive and use machines

NORSPAN® patch has a major influence on the ability to drive and use machines. Even when used according to instructions, buprenorphine may modify patients' reactions to a varying extent depending on the dosage and individual susceptibility such that road safety and the ability to operate machinery may be impaired. This applies particularly in the beginning of treatment, during titration to a higher dose and in conjunction with other centrally acting substances including alcohol, tranquillisers, sedatives and hypnotics. If affected, patients should not drive or operate machinery for at least 24 hours after the NORSPAN® patch has been removed.

4.8 Undesirable effects

Adverse reactions that may be associated with NORSPAN® patch therapy in clinical use are similar to those observed with other opioid analgesics and tend to reduce with time, with the exception of constipation.

The following adverse reactions have been reported:

Immune system disorders

Uncommon	hypersensitivity(including oropharyngeal swelling and swollen tongue)
Rare	anaphylactic responses
Very rare	serious allergic reactions

NEW ZEALAND DATA SHEET

Metabolism and nutrition disorders

Common anorexia
Uncommon dehydration*, weight decreased

Psychiatric disorders

Common anxiety, confusional state, depression*, insomnia, nervousness
Uncommon affect lability, agitation, depersonalisation, euphoric mood, hallucination, libido decreased, nightmare, aggression
Rare psychotic disorder
Very rare dependence, mood swings
Unknown drug dependence

Nervous system disorders

Very Common dizziness, headache*, somnolence*
Common dysgeusia (taste disturbance), paraesthesia, tremor

Uncommon concentration impairment, coordination abnormal, dysarthria, hypoaesthesia, memory impairment, migraine, restlessness, sedation, sleep disorder, syncope*

Rare dysequilibrium, numbness

Not Known convulsions
hyperalgesia
sleep apnoea syndrome

Eye disorders

Uncommon dry eye, vision blurred
Rare eyelid oedema, miosis, visual disturbance

Ear and labyrinth disorders

Uncommon tinnitus, vertigo
Very rare ear pain

Cardiac disorders

Uncommon angina pectoris, palpitations, tachycardia

Vascular disorders

Common vasodilatation
Uncommon circulatory disorders (such as hypotension or rarely even circulatory collapse), flushing, hypertension*, orthostatic hypotension

Respiratory, thoracic and mediastinal disorders

Common dyspnoea*
Uncommon asthma aggravated*, cough, hiccups, hyperventilation, hypoxia, rhinitis*, wheezing*
Rare respiratory depression, respiratory failure*

NEW ZEALAND DATA SHEET

Gastrointestinal disorders

Very Common	constipation*, dry mouth, nausea*, vomiting*
Common	abdominal pain*, diarrhoea*, dyspepsia*
Uncommon	flatulence
Rare	diverticulitis*, dysphagia, ileus, pyrosis (heartburn)
Very rare	retching

Hepatobiliary disorders

Rare	billiary colic
------	----------------

Skin and subcutaneous tissue disorders

Very Common	pruritus*
Common	exanthema, rash*, sweating*
Uncommon	dry skin, face oedema, urticaria
Very rare	pustules, vesicles

Musculoskeletal and connective tissue disorders

Uncommon	muscle cramps, muscle spasm, myalgia
Very rare	muscle fasciculation

Renal and urinary disorders

Uncommon	urinary incontinence, urinary retention
Rare	urinary hesitation

Reproductive system and breast disorders

Rare	decreased erection, sexual dysfunction
------	--

General disorders and administration site conditions

Very common	application site skin reaction [†] **
Common	asthenic conditions* (including muscle weakness, lethargy, fatigue and malaise), pain, peripheral oedema, tiredness
Uncommon	oedema, pyrexia*, rigors*, drug withdrawal syndrome, chest pain*,
Rare	influenza-like illness
Not known	Drug withdrawal syndrome neonatal Drug tolerance

Injury, poisoning and procedural complications

Uncommon	accidental injury (including fall)
----------	------------------------------------

Investigations

Uncommon	Alanine aminotransferase increased Weight decreased
----------	--

Very Common	≥ 10%
Common	≥ 1% and < 10%
Uncommon	≥ 0.1% and < 1%
Rare	≥ 0.01% and < 0.1% (isolated cases)
Very rare	< 0.01%

* at least one serious case

NEW ZEALAND DATA SHEET

[†]Include common signs and symptoms of contact dermatitis (irritative or allergic): erythema, oedema, pruritus, rash, vesicles, painful/burning sensation at the application site.

******In some cases late onset local allergic reactions (allergic contact dermatitis) occurred with marked signs of inflammation. In such cases treatment with NORSPAN[®] should be terminated (see sections 4.3 and 4.4).

The incidence of adverse events did not vary with age or race. The incidence of most adverse events was similar for males and females, but females reported nausea, vomiting, dizziness and headache 10% to 15% more frequently than males.

Application Site Skin Reactions

In rare cases, severe application site skin reactions with signs of marked inflammation including “burn,” “discharge,” and “vesicles” have occurred. Time of onset varies, ranging from days to months following the initiation of NORSPAN[®] patch. Instruct patients to promptly report the development of severe application site reactions and discontinue therapy.

Anaphylactic/Allergic Reactions

Cases of acute and chronic hypersensitivity to buprenorphine have been reported uncommonly both in clinical trials and in the post-marketing experience. The most common signs and symptoms include rashes, hives, and pruritus. Cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported. A history of hypersensitivity to buprenorphine is a contraindication to the use of NORSPAN[®] patch.

Reporting suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>

NEW ZEALAND DATA SHEET

4.9 Overdose

The manifestations of buprenorphine overdose are an extension of its pharmacologic actions. Respiratory depression has been absent in some cases of buprenorphine overdose. However, respiratory depression, including apnoea, has occurred in other overdose situations. Additional symptoms include sedation, drowsiness, nausea, vomiting, cardiovascular collapse and marked miosis.

Remove any patch in contact with the patient and dispose of it properly. Establish and maintain a patent airway, assist or control respiration as indicated and maintain adequate body temperature and fluid balance. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated.

A specific opioid antagonist, such as naloxone, may reverse the effects of buprenorphine, although naloxone may be less effective in reversing the effects of buprenorphine than other μ -agonists. Treatment with continuous intravenous naloxone should begin with the usual doses but high doses may be required.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800764766).

5 PHARMACOLOGICAL PROPERTIES


5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Analgesics, opioids

ATC code: N02 AE01

Buprenorphine base (active). CAS Registry Number 52485-79-7.

The structural formula is:



Buprenorphine is a white or almost white powder and is very slightly soluble in water, freely soluble in acetone, soluble in methanol and ether and slightly soluble in cyclohexane. The pKa is 8.5. The chemical name of buprenorphine is (2S)-2-[17-(cyclopropylmethyl)-4, 5 α -epoxy-3-hydroxy-6-methoxy-6 α , 14-ethano-14 α -morphinan-7 α -yl]-3, 3-dimethylbutan-2-ol. The molecular weight is 467.6 and the empirical formula is C₂₉H₄₁NO₄.

Buprenorphine is a μ -opioid agonist, acting at mu-opioid receptors. The opioid agonist activities of buprenorphine are dose related. Buprenorphine also has antagonistic activity at the kappa-opioid receptor. It is classified as a psychotropic substance under international convention.

Like other opioid agonists, buprenorphine produces dose-related analgesia, however, a ceiling effect to analgesia is well documented. Buprenorphine binds to and dissociates from the mu-receptor slowly, which may account for the prolonged duration of analgesia and, in part, for the limited physical dependence potential observed with the medicine.

NEW ZEALAND DATA SHEET

Buprenorphine produces similar effects to other opioids on the central nervous, cardiovascular, respiratory and gastrointestinal systems, although the intensity and duration of the effects may vary when compared with other opioids. Opioids may also influence the hypothalamic-pituitary-adrenal or –gonadal axes, including an increase in serum prolactin and decreases in plasma cortisol and testosterone, which can manifest in clinical symptoms.

Since kappa-receptor agonist activity is related to psychotomimetic and dysphoric effects, buprenorphine is expected to produce fewer psychotomimetic and dysphoric effects than medicines with kappa-agonist activities.

Like other opioid agonists, buprenorphine may produce increases in cerebrospinal fluid pressure, cause altered mentation, mental clouding or amnesia.

Buprenorphine acts to reduce blood pressure in a manner similar to other opioids. NORSPAN® patch application resulted in transient decreases in blood pressure in healthy young and elderly subjects, without clinical adverse events.

Like other opioid analgesics, buprenorphine has a potential of respiratory depression. Respiratory depression is less common than with full mu-agonists, such as morphine, and there appears to be a ceiling effect. However, evidence suggests that buprenorphine is a partial agonist with respect to its respiratory depressant activity. When respiratory depression occurs it appears to have a slower onset and longer duration compared with morphine.

Administration of buprenorphine to persons who are physically dependent on full mu-opioid agonists may precipitate an abstinence syndrome depending on the level of physical dependence, and the timing and dose of buprenorphine.

Like other opioids buprenorphine may cause nausea, vomiting, constipation and an increase in biliary tract pressure. Effects on the immune system were seen with natural opioids like morphine in in vitro and animal studies, although the clinical significance of these is unknown. It is not known whether buprenorphine, a semisynthetic opioid, has immunological effects similar to morphine.

Buprenorphine can cause dose-related miosis and urinary retention in some patients.

Clinical Trials

The safety and efficacy of NORSPAN® patch in the management of chronic pain has been studied in 10 clinical trials [1,698 patients treated with NORSPAN® patch]. The active and placebo-controlled clinical trials included patients with moderate to severe, chronic pain of osteoarthritis, low back and non-cancer pain requiring opioid analgesia. A single trial examined the safety of three doses of NORSPAN® patch given for 72 hours to patients following orthopaedic surgery. No trials have been conducted in patients with cancer related pain.

BUPN.CLIN0001 was a randomised, double-blind, double dummy, parallel, equivalence study comparing the efficacy and tolerability of NORSPAN® patch 5, 10 and 20mg applied every seven days with sublingual buprenorphine tablets 200 and 400mcg [Temgesic] in 238 patients with moderate to severe pain due to osteoarthritis [hip and/or knee, 85% >one year]. Patients were titrated to optimum pain control over 21 days, and continued at this level for 28 days. Paracetamol was permitted for breakthrough pain and all usage recorded. The primary efficacy variable was pain intensity recorded during the assessment period [Days three and seven, BS-11 scale - see Table 1]. The Per Protocol mean NORSPAN® PATCH – NORSP010

NEW ZEALAND DATA SHEET

reductions in pain scores ranged from 2.6 to 3.6 across the three daily rating assessments (morning, midday, evening) and the estimated mean difference between both active treatment arms was minimal [range 0.001 to 0.13]. The 95% confidence intervals for the difference between treatments were within the range -1 to 1, compared with the pre-specified equivalence margins of -1.5 to 1.5. This demonstrated equivalent efficacy. At study completion 70% [40/51] of patients on patch and 75% [42/51] on tablets rated their pain relief as good or very good.

Table 1 Pain intensity scores in study BUPN.CLIN0001

	Transdermal buprenorphine patches	Sublingual buprenorphine tablets
Dose	Titration to optimum pain control over 21 days with same dose continued for up to 28 days	200 or 400mcg 6-8 hourly
Mean baseline pain intensity*	6.1	6.3
Mean pain intensity scores during assessment [Day 7]*	3.2	3.2

There was no difference in escape medication usage and the incidence of discontinuation due to lack of efficacy was similar between the two treatment groups [9% Temgesic vs 14% NORSPAN® patch]. The most common adverse events reported were those commonly associated with the use of opioids (nausea, vomiting, dizziness, somnolence, headache and constipation).

BP98-1201 was a randomised, double-blind trial comparing the efficacy and safety of NORSPAN® patches 5, 10 and 20mg, applied every seven days, with hydrocodone/paracetamol [2.5mg/250mg] tablets four times a day (qid) in 270 patients with chronic moderate to severe back pain [pain intensity ≥ 5 BS-11 scale], not controlled by non-opioid analgesia alone [ibuprofen 400mg qid]. Patients were titrated to optimum pain control over 21 days, and continued at this level for 35 days. The primary efficacy variables were average pain intensity [BS-11 scale*] and patient satisfaction with medication over Days 21-56+, refer Table 2. The Intent to Treat (ITT) population mean baseline pain intensity was 7.74 (NORSPAN® patch group) compared with 7.65, which reduced through Days 21-56 to 5.96 and 6.04, respectively. The difference (and 95% confidence interval) in average pain intensity between the two treatments was -0.08 [-0.06 to 0.44]. The difference between the two treatments in patient global satisfaction was 0.16 [-0.08 to 0.39]. NORSPAN® patch was equally effective as hydrocodone/paracetamol tablets in relieving pain and for patient satisfaction.

Table 2 Pain intensity scores in study BP98-1201

	Transdermal buprenorphine patches	Hydrocodone/paracetamol tablets
Dose	Titration to optimum pain control over 21 days, with same dose continued for 35 days	1 to 3 hydrocodone/paracetamol [2.5mg/250mg] tablets four times daily
Mean baseline pain intensity*	7.74 [7.5 to 8.0]	7.65 [7.4 to 7.9]
Reduction in pain intensity from baseline to end of study*	1.78	1.61
Average pain intensity over Days 21-56*	5.96 [5.6 to 6.3]	6.04 [5.7 to 6.4]
Patient global satisfaction with medication over Days 21-56 [†]	1.53 [1.4 to 1.7]	1.37 [1.2 to 1.5]

* Pain intensity was assessed by the BS-11 pain scale, an 11-point scale for rating current pain, where 0 = "no pain" and 10 = "pain as bad as you can imagine"

[†] Patient global satisfaction with medication was assessed on a 4-point scale, with the question "Rate the study medication you received for pain"

NEW ZEALAND DATA SHEET

The majority of adverse events reported were mild or moderate in severity and were typically associated with opioid therapy. Withdrawals due to lack of efficacy was similar for both groups (15% for NORSPAN® patch and 14% for hydrocodone/paracetamol). No changes in laboratory values were considered related to treatment, and no clinically important changes were reported for pulse rate, respiratory rate or physical examinations.

5.2 Pharmacokinetic properties

Each NORSPAN® patch provides a steady delivery of buprenorphine for up to seven days. Steady state is achieved by day three following the first application. After removal of a NORSPAN® patch buprenorphine concentrations initially decline at a rate of approximately 50% in 12 hours. Thereafter, mean elimination half-lives have been reported to be between 30 and 45 hours.

Absorption

Following NORSPAN® patch application, buprenorphine diffuses from the patch through the skin. In clinical pharmacology studies, the median time for NORSPAN® patch 10 micrograms per hour to deliver detectable buprenorphine concentrations (100 picograms/mL) was approximately 17 hours. The mean bioavailability of buprenorphine from a NORSPAN® patch relative to intravenous (IV) dosing is 15% (for all three strengths).

The absorption does not vary significantly across the specified application sites. Mean exposure (AUC) at each of the application sites is within approximately +/- 11% of the mean exposure for the four sites; upper outer arm, upper chest, upper back and the side of the chest.

Accidental oral ingestion: Measurable systemic levels of buprenorphine were demonstrated in dogs given NORSPAN® patch by oral administration.

Distribution

Buprenorphine is approximately 96% bound to plasma proteins.

In a study of IV buprenorphine in healthy subjects, the volume of distribution at steady state was 430L, which is indicative of the high lipophilicity of the medicine.

Following IV administration, buprenorphine and its metabolites are secreted into bile, and within several minutes distribute into the cerebrospinal fluid (CSF). CSF concentrations appear to be approximately 15% to 25% of concurrent plasma concentrations.

Biotransformation and Elimination

Buprenorphine metabolism in the skin following NORSPAN® patch application is negligible. Buprenorphine is eliminated via hepatic metabolism, with subsequent biliary excretion and renal excretion of soluble metabolites. Hepatic metabolism through CYP3A4 and UGT1A1/1A3 enzymes, results in two primary metabolites, norbuprenorphine and buprenorphine 3-O-glucuronide. Norbuprenorphine is also glucuronidated prior to elimination. Buprenorphine is also eliminated in the faeces within seven days.

Norbuprenorphine is the only known active metabolite of buprenorphine. It has been shown to be a respiratory depressant in rats at concentration at least 50-fold those seen following application of NORSPAN® patch 20 micrograms per hour.

In a study in postoperative patients the total clearance of buprenorphine was 55L/h.

NEW ZEALAND DATA SHEET

Application Site

A study in healthy subjects demonstrated that the pharmacokinetic profile of buprenorphine delivered by NORSPAN® patch is similar when applied to the upper outer arm, upper chest, upper back or the side of the chest (midaxillary line, 5th intercostal space).

In a study of healthy subjects applying NORSPAN® patch repeatedly to the same site, immediate reapplication caused increased absorption, without clinical adverse events. For this reason, rotation of application sites is recommended (see Section 4.2 Dosage and Administration).

In another study in healthy subjects application of a heating pad directly on the NORSPAN® patch caused a transient, 26-55% increase in blood concentrations of buprenorphine. Concentrations returned to normal within five hours after the heat was removed. For this reason, applying heat sources such as hot water bottles, heat pads or electric blankets directly to the NORSPAN® patch is not recommended. A heating pad applied to a NORSPAN® patch site directly after patch removal did not alter absorption from the skin depot.

5.3 Preclinical safety data

Systemic toxicity and dermal toxicity

In single- and repeat-dose toxicity studies in rats, rabbits, guinea pigs, dogs, and minipigs, NORSPAN® caused minimal or no adverse systemic events, whereas skin irritation was observed in all species examined. Toxicological data available did not indicate a sensitising potential of the additives of the transdermal patches

Genotoxicity and carcinogenicity

A standard battery of genotoxicity tests indicated that buprenorphine is non-genotoxic. In long-term studies in rats and mice there was no evidence of any carcinogenic potential relevant for humans.

Reproductive and developmental toxicity

No effect on fertility or general reproductive performance was observed in rats treated with buprenorphine. No embryofetal toxicity effects were observed in rats or rabbits. In a rat pre- and post-natal development toxicity study with buprenorphine there was pup mortality and decreased pup body weight at maternal doses that produced a reduction in food consumption and clinical signs.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Inert ingredients

Levulinic acid

Oleyl oleate

Povidone (PVP)

Duro Tak 387-2051

Duro Tak 387-2054

Polyethylene terephthalate (PET)

6.2 Incompatibilities

None known

NEW ZEALAND DATA SHEET

6.3 Shelf life

36 months

6.4 Special precautions for storage

Store below 25°C

6.5 Nature and contents of container

NORSPAN® patch is supplied a heat-sealed aluminium/anionic methacrylate laminate pouch. Each carton contains two individually packaged patches.

6.6 Special precautions for disposal

Disposal after use:

When changing the transdermal system, remove the used NORSPAN®, fold it over on itself (bringing the adhesive sides together) and dispose of safely, out of the reach of children.

7 MEDICINE SCHEDULE

Controlled Drug C4

8 SPONSOR

Distributed on behalf of Mundipharma New Zealand Limited by:

Pharmaco (N.Z.) Ltd

Fisher Crescent

Mt Wellington

Auckland 1060

Ph: (09) 377-3336

Toll Free [Medical Enquiries]: 0800 773 310

9 DATE OF FIRST APPROVAL

16 November 2006

10 DATE OF REVISION OF THE TEXT

19 August 2022

[CCDS V14, 15 Sept 2021]

® NORSPAN is a registered trade mark of MUNDIPHARMA.

SUMMARY TABLE OF CHANGES

Section changed	Summary of new information
Section 4.4 and 4.5	Update to remove the mention of serotonin syndrome according to MARC recommendations